Transfusional Iron Overload

Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

Treatment of Iron Overload Requiring Chelation Therapy

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

High-Tc Susceptometer to Monitor Transfusional Iron Overload

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Active Drug Surveillance Program of Ferriprox Use

Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload